The Incorrect Statement is E
The presence of a thyroid nodule in a patient with Hashimoto's thyroiditis and normal TSH levels is NOT an indication for thyroid hormone replacement therapy. This statement is incorrect because thyroid hormone replacement is indicated for hypothyroidism (elevated TSH), not for the mere presence of a nodule with normal thyroid function 1, 2.
Analysis of Each Statement
Statement A: Most Common Thyroid Disorder - CORRECT
Hashimoto's thyroiditis is indeed the most common cause of hypothyroidism in iodine-sufficient areas like the United States 2. Multiple recent studies confirm it remains the most prevalent autoimmune thyroid disease globally 3, 4, 5, 6.
Statement B: Associated with Anti-TPO Antibodies - CORRECT
Anti-thyroid peroxidase (anti-TPO) antibodies are present in approximately 75% of patients with chronic autoimmune thyroiditis 2. Anti-TPO antibodies are found in over 90% of Hashimoto's cases and are the most sensitive marker for the disease 4, 5. The presence of elevated TPOAb titers helps predict progression to overt hypothyroidism at a rate of 4.3% per year versus 2.6% without elevated antibodies 2.
Statement C: More Common in Women - CORRECT
Autoimmune thyroid diseases are estimated to be 5-10 times more common in women than men 2. Hashimoto's affects women 7-10 times more often than men 4. This female predominance is consistently documented across multiple studies 3, 7.
Statement D: Can Manifest as Hypothyroidism or Hyperthyroidism - CORRECT
The clinical presentation of Hashimoto's includes three phases 4:
- Thyrotoxicosis (Hashitoxicosis): When stored thyroid hormones are released from destroyed thyroid follicles
- Euthyroidism: When preserved thyroid tissue compensates for destroyed thyrocytes
- Hypothyroidism: When thyroid hormone production becomes insufficient
This transient hyperthyroid phase is well-documented and represents the initial destructive phase of the disease 8.
Statement E: Nodule with Normal TSH Requires Replacement - INCORRECT
This is the false statement. The guidelines are explicit that thyroid hormone replacement therapy is indicated based on thyroid function (TSH elevation), not based on the presence of nodules alone 1, 2.
Key Evidence Against Statement E:
Normal TSH = No indication for replacement therapy: When TSH is normal, levothyroxine is not indicated for hypothyroidism treatment 2
Nodules require different management: The guideline states that "patients with documented hypothyroidism" should have measurement of antibodies when nodules are present, and fine-needle aspiration may be needed to exclude malignancy 2. However, this is for diagnostic purposes, not an automatic indication for hormone replacement.
TSH suppression is selective: The guidelines specify that TSH suppression with levothyroxine is indicated for certain thyroid cancers and some thyroid nodules, but this decision should be reviewed by an endocrinologist 1. This is not a blanket recommendation for all nodules with normal TSH.
Treatment threshold: Levothyroxine therapy should be started promptly in frank hypothyroidism, but treatment of subclinical hypothyroidism (elevated TSH with normal free T4) is more debated, particularly when TSH is only mildly elevated 8
Clinical Pitfall to Avoid
Do not confuse the presence of thyroid nodules in Hashimoto's patients with an indication for hormone replacement. The indication for levothyroxine is biochemical hypothyroidism (elevated TSH), not structural changes alone. Nodules in Hashimoto's patients warrant evaluation for malignancy (1.6 times higher risk of papillary thyroid cancer and 60 times higher risk of thyroid lymphoma) 4, but normal thyroid function does not require hormone replacement therapy.